Replimune Group (NASDAQ:REPL) Trading Down 3.4%

Replimune Group, Inc. (NASDAQ:REPL) fell 3.4% during trading on Tuesday . The stock traded as low as $8.97 and last traded at $9.04. 46,156 shares traded hands during trading, a decline of 97% from the average session volume of 1,332,680 shares. The stock had previously closed at $9.36.

Analyst Ratings Changes

A number of brokerages recently issued reports on REPL. HC Wainwright increased their target price on Replimune Group from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research note on Thursday, June 6th. Finally, Barclays lifted their price objective on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Friday, June 7th.

Replimune Group Stock Performance

The company has a quick ratio of 10.72, a current ratio of 10.72 and a debt-to-equity ratio of 0.18. The stock has a fifty day moving average price of $7.03 and a two-hundred day moving average price of $7.63.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, May 16th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.04. Equities research analysts anticipate that Replimune Group, Inc. will post -3.31 EPS for the current fiscal year.

Insider Activity

In related news, COO Colin Love sold 17,615 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $6.47, for a total transaction of $113,969.05. Following the transaction, the chief operating officer now directly owns 777,345 shares in the company, valued at $5,029,422.15. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Chairman Philip Astley-Sparke sold 37,928 shares of Replimune Group stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total transaction of $245,394.16. Following the sale, the chairman now directly owns 1,487,350 shares in the company, valued at approximately $9,623,154.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Colin Love sold 17,615 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $6.47, for a total transaction of $113,969.05. Following the completion of the transaction, the chief operating officer now directly owns 777,345 shares in the company, valued at $5,029,422.15. The disclosure for this sale can be found here. Insiders sold a total of 107,598 shares of company stock worth $712,516 over the last quarter. Insiders own 20.60% of the company’s stock.

Institutional Trading of Replimune Group

Several hedge funds have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC increased its stake in shares of Replimune Group by 45.3% during the 3rd quarter. Hsbc Holdings PLC now owns 19,718 shares of the company’s stock worth $325,000 after purchasing an additional 6,144 shares during the last quarter. Alps Advisors Inc. grew its holdings in Replimune Group by 2.6% during the third quarter. Alps Advisors Inc. now owns 43,550 shares of the company’s stock valued at $745,000 after purchasing an additional 1,083 shares during the period. Graham Capital Management L.P. purchased a new stake in Replimune Group in the third quarter worth $340,000. Wellington Management Group LLP raised its stake in shares of Replimune Group by 25.2% in the third quarter. Wellington Management Group LLP now owns 261,277 shares of the company’s stock valued at $4,470,000 after buying an additional 52,633 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Replimune Group by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,596,119 shares of the company’s stock valued at $44,420,000 after buying an additional 242,220 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.